SPYRAL HTN Global Clinical Trial

Novel Artificial Heart Valve In Low-Risk Aortic Stenosis Trial

Ascension Providence Hospital, Southfield Campus is one of the first institutions in the U.S. enrolling patients to participate in a study investigating a medical device to help lower blood pressure in patients with uncontrolled hypertension. This chronic condition is defined as an average systolic blood pressure at or above 140 mmHg. If left untreated, it can significantly increase the risk of heart attack, stroke, heart failure, kidney disease and death.

Ascension Providence Hospital is participating in two new global clinical trials investigating the effect of renal denervation with the investigational Symplicity Spyral™ catheter and Symplicity G3™ radiofrequency (RF) generator. Renal denervation is a minimally invasive, catheter-based procedure that may potentially calm the activity of nerves within the arteries leading to the kidneys. These nerves are part of the sympathetic nervous system, which helps the body control blood pressure. In people with hypertension, the renal nerves are hyperactive, raising blood pressure and contributing to heart, kidney and blood vessel damage.

The two separate trials enrolling at Ascension Providence Hospital are investigating the effect of renal denervation on high blood pressure in patients who are and who are not taking medications to lower their blood pressure.

“Uncontrolled high blood pressure is one of the greatest threats to patients in metro Detroit,” said Shukri David, chief of cardiology at the Ascension Providence Heart Institute and the principal investigator of the trials at Ascension Providence Hospital. “We are proud to have been selected to take part in these groundbreaking trials, and look forward to helping identify which patients might be the most appropriate for this investigational treatment.”

Together these trials are part of Medtronic’s SPYRAL HTN Global Clinical Trial Program, a unique, multi-phased clinical study strategy to clearly understand effect of renal denervation on uncontrolled hypertension.

Contact Us About The SPYRAL HTN Global Clinical Trial

Potential study participants should call 248-849-3369 for more information.